Limited Submission: Pilot Projects in Non-AIDS Defining Cancers
LOI: September 5, 2017
Full Application: September 11, 2017
With support from a supplement to its NCI P30 grant, the Case Comprehensive Cancer Center in coordination with the CWRU/UH Center for AIDS Research (CFAR) is providing seed funding for the development of cancer research projects focusing on the interface between aging and HIV infection in Non-AIDS Defining Cancers (NADC). The goal of this RFA is to build collaborative projects in cancer biology, aging, immunology, HIV/AIDS, systems biology/informatics, geriatric oncology, geriatric epidemiology, and/or cancer survivorship that will be competitive for nationally-funded multi-PI awards.
- Funding for research teams with a focus on unique aspects of aging and NADC in HIV positive patients
- TWO research projects will be awarded
- Each research project will be funded at a level up to $50,000 for one year
- Applications must focus on NADC in HIV-positive patients
- Interactions with HIV research teams and/or patient cohorts from the CWRU/UH CFAR and/or Uganda is strongly encouraged
- Use of the national CFAR Network of Integrated Clinical Systems (CNICS) database and CWRU/UH CFAR database is encouraged
- Strong collaborative investigative teams led by independent faculty at any one or more of the Case CCC institutions
- Highly innovative and impactful projects
- Projects must have a high likelihood of subsequent national-level funding of multi-PI grants
- Strong biostatistical or bioinformatic support
- Limit of ONE application per lead PI. Investigators can be collaborators on multiple applications
- NON-COMPETING Letter of Intent (1 page) to aide reviewer identification is due September 5
- All applications will be reviewed in two stages that include 1) evaluation of the research proposed in the written proposal
- Applications must follow the specific instructions for this RFA
- Case CCC Pilot Application Cover Page [View pdf: Case CCC-pilot-app-cover-template]
- Case CCC Pilot Application Budget Form [View pdf: CaseCCC-pilot-app-budget-form-singleyr]
- Instructions [View pdf: NADC-instructions-2017]
John Pounardjian, Cancer Center Administration: 216.844.8326, email@example.com
Projects Supporting Multi-Investigator Research Programs in Adolescent and Young Adult (AYA) Cancers
LOI: September 11, 2017 (LOI)
Stage I: October 1, 2017 (Stage I)
With support from the Angie Fowler AYA Cancer Research Initiative, the Case Comprehensive Cancer Center is providing seed funding for the development of multi-investigator research programs focused on cancers in the adolescent and young adult (AYA) population (ages 15-30). Each year in the United States, approximately 70,000 adolescents and young adults are diagnosed with cancer. The goal of this RFA is to support teams of three or more principal investigators who are working to develop and submit a program project or similar level grant application focused on AYA cancers. Research teams must focus on the discovery of novel AYA cancer mechanisms with the expectation that these insights will lead to new diagnostics, prognostics, and/or therapeutics. Teams must provide evidence of an ongoing collaboration, but may also add new participants to the collaborative team.
Funds from this RFA will be prioritized for investigators that are currently participating in the AYA working group. However, teams that have not yet been members of this group, but feel they can provide a responsive proposal and wish to join the group, may submit a Letter of Intent requesting consideration. Responsive proposals should address diseases occurring in the AYA population such as ALL, Brain Tumors, Sarcomas, Melanoma, AYA patients from high risk families, or patients within the AYA range that develop cancers that more commonly occur in older adults (eg. Breast, Colon). Projects of particular interest include those that focus on Hematopoietic Stem Cell Biology, Immunotherapy/Cellular therapy, Drug Development, Chemoprevention, Cancer Imaging, Genomics, or Biomarker Development. Responsive proposals should demonstrate clear relevance to AYA cancers. It is expected that funded projects will lead to nationally competitive grant proposals from multi-investigator teams of three or more PIs. To enhance competitiveness for national funding, the research team is expected to have identified a proposal coach within Cleveland that has experience with multi-investigator projects and can advise the team regarding development of the federal proposal. In addition, the team may identify an external advisor from outside Cleveland.
- Funding for research teams with a focus on AYA cancers. Projects not specifically targeted to AYA cancers will be considered unresponsive.
- Up to 3 research programs (each with at least 3 research projects) will be funded.
- Each research program can request a budget of up to $300,000 for 1.5 years. Up to $25,000 can be budgeted for administrative support, support of the proposal coach, or travel of the external advisor.
A three-stage review process will be used to select funded programs (teams not currently participating in the AYA working group have an additional requirement of submitting an LOI and then being invited to submit)
- LOI: Submission of a one page proposal including title, research scope, and investigative team. These are required for teams whose members are not currently participating in the AYA working group and are due by September 11, 2017.
- Stage 1: Submission of proposals with a global Specific Aims Page, Specific Aims pages for each project, Description of Research Team, Biosketches for each project PI, and Description of ongoing collaborative activities.
- Stage 2: Selected applicants will present their proposed program to Executive Committee of the Case Comprehensive Cancer Center.
- Stage 3: Detailed applications will be requested for formal review.
- Strong collaborative investigative teams with expertise in AYA (ages 15-30) cancers is essential.
- Programs must have a high likelihood of subsequent national-level funding for PPG, SPORE, or similar grants.
- Programs must include three or more highly innovative and impactful projects that specifically focus on AYA cancers.
John Pounardjian, Cancer Center Administration: 216.844.8326, firstname.lastname@example.org
PILOT PROJECT GRANTS: American Cancer Society IRG Awards
Letter of Intent Deadline: Thursday, September 21, 2017
Application Deadline: Monday, October 9, 2017
- Pilot funding for cancer-related research in basic, clinical, prevention & control, behavioral, health services and epidemiology.
- Up to $30,000 award.
- Applications accepted for general cancer-related projects and for special interest projects in adolescent-and-young-adult cancer research.
IRG pilot project grants are intended to support independent, self-directed investigators early in their careers (usually assistant professor or equivalent). Applicants for the pilot project grants should be within 6 years of their first independent research or faculty appointment and eligible to apply for an independent national competitive research grant, but do not currently hold such a cancer-related grant.
Recipients of IRG pilot project grants must be, at the time of the application, citizens or noncitizen nationals of the United States or its possessions and territories, or must have been lawfully admitted to the United States for permanent residence at the time of application.
- Case CCC Pilot Application Cover Page Template [View pdf: Case CCC-pilot-app-cover-template]
- Case CCC Pilot Application LOI Template [View pdf: CaseCCC-pilot-app-LOI-template]
- Instructions [View pdf: ACS-RFA-Summer-2017-instructions]
- Application Form [View doc: ACS-RFA-Summer-2017-application-form]
- Frequently Asked Questions [View pdf: ACS-RFA-Summer-2017-FAQs]
Julie Glavic, Cancer Center Administration, 216.368.5780, email@example.com
Request for Proposals for Case CCC Funding for Pilot/Phase I Clinical Trials
The Case CCC is encouraging investigators to submit Letters of Intent (LOI) for Early Phase Clinical Research Support (EPCRS) funding. These in-house funds are available for the conduct of early phase clinical trials of relatively short duration. Priority will be given to trials which are developed jointly between UH and CCF with planned accrual at both institutions.
The proposals are being accepted on a rolling basis subject to availability of funds.
Please direct any questions and/or submit LOIs to Katarzyna Karelus, Case CCC Clinical Research Office, firstname.lastname@example.org, 216.844.4176.